Show simple item record

dc.contributor.authorCortese, Samuele
dc.date.accessioned2017-08-24T14:53:34Z
dc.date.available2017-08-24T14:53:34Z
dc.date.issued2014
dc.identifier.citationPurgato, M. & Cortese, S. (2014). Does psychostimulant treatment in children with ADHD increase later risk of substance use disorder? Epidemiology and Psychiatric Sciences, 23 (2), pp.133-135.
dc.identifier.other10.1017/S2045796014000146
dc.identifier.urihttp://hdl.handle.net/20.500.12904/7667
dc.description.abstractPsychostimulants are the first choice medication in children with attention-deficit/hyperactivity disorder (ADHD). Despite the proven high efficacy of psychostimulants, at least in the short term, for ADHD core symptoms, concerns continue to be raised on their adverse effects, including putative increased risk of substance use disorders (SUDs). A recent multicentre, case-control, longitudinal, prospective, European study by Groenman and colleagues found that treatment with psychostimulants in children with ADHD lowered the risk of SUDs in adolescence. However, this finding is at odds with other recent evidence concluding that ADHD children with and without medication treatment history did not significantly differ on any subsequent SUDs rates. In the present paper, we discuss the study by Groenman and colleagues in view of its methodological strengths and limitations, and we suggest possible implications for day-to-day clinical practice. Copyright © Cambridge University Press 2014.
dc.description.urihttps://www.cambridge.org/core/journals/epidemiology-and-psychiatric-sciences/article/div-classtitledoes-psychostimulant-treatment-in-children-with-adhd-increase-later-risk-of-substance-use-disorderdiv/E4160941D93AC6F47019069D1BF5B644
dc.subjectAttention deficit disorder with hyperactivity
dc.subjectSubstance-related disorders
dc.titleDoes psychostimulant treatment in children with ADHD increase later risk of substance use disorder?
dc.typeArticle
html.description.abstractPsychostimulants are the first choice medication in children with attention-deficit/hyperactivity disorder (ADHD). Despite the proven high efficacy of psychostimulants, at least in the short term, for ADHD core symptoms, concerns continue to be raised on their adverse effects, including putative increased risk of substance use disorders (SUDs). A recent multicentre, case-control, longitudinal, prospective, European study by Groenman and colleagues found that treatment with psychostimulants in children with ADHD lowered the risk of SUDs in adolescence. However, this finding is at odds with other recent evidence concluding that ADHD children with and without medication treatment history did not significantly differ on any subsequent SUDs rates. In the present paper, we discuss the study by Groenman and colleagues in view of its methodological strengths and limitations, and we suggest possible implications for day-to-day clinical practice. Copyright © Cambridge University Press 2014.


This item appears in the following Collection(s)

Show simple item record